Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group

British Journal of Cancer

Volumn 107, Issue 3, 2012, Pages 442-447

  Flotten o ^a   Gronberg B H ^b,c   Bremnes, R ^d,e   Amundsen, T ^b,f   Sundstrom S ^b   Rolke, H ^g   Hornslien, K ^h   Wentzel Larsen, T ^a,i,j   Aasebo U ^d,e   Von Plessen, C ^k,l  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

^e UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^g Sørlandet Hospital Kristiansand   (Norway)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^j Norwegian Centre for Violence and Traumatic Stress Studies   (Norway)

^k HILLERØD HOSPITAL   (Denmark)

^l UNIVERSITY OF BERGEN   (Norway)

more..

Author keywords

advanced NSCLC; carboplatin; gemcitabine; lung cancer; palliative chemotherapy; vinorelbine

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; ERLOTINIB; GEMCITABINE; GLUCOCORTICOID; NAVELBINE; PEMETREXED; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NORWAY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; QUALITY OF LIFE; VINBLASTINE;

EID: 84864374720     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.284     Document Type: Article

References (35)

1. Aapro M, Finek J (2011) Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results. Cancer Treat Rev 38(2): 120-126
2. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a qualityof-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376
3. Azzoli CG, Baker Jr S, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27: 6251-6266
4. Azzoli CG, Temin S, Aliff T, Baker Jr S, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2011) 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 29: 3825-3831
5. Barlesi F, Pujol JL (2005) Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: A systematic review of phase III trials. Lung Cancer 49: 289-298
6. Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A: 1135-1141
7. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432-1440
8. D'Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E (2010) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5): v116-v119
9. Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) On Behalf of the EORTC Quality of Life Groups: The EORTC QLQ-C30 Scoring Manual 3rd edition. European Organisation for Research and Treatment of Cancer: Brussels
10. Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK (2010) First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 5: 260-274
11. Gralla RJ, Gatzemeier U, Gebbia V, Huber R, O'Brien M, Puozzo C (2007) Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management. Drugs 67: 1403-1410
12. Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD (2007) Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer 8: 483-487
13. Gronberg BH, Bremnes RM, Flotten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollali T, Wammer F, Aasebo U, Sundstrom S (2009) Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27: 3217-3224
14. Han JY, Lee DH, Song JE, Lee SY, Kim HY, Kim HT, Lee JS (2008) Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer. Cancer 113: 388-395
15. Harrell FE (2003) Hmisc S function library. http://hesweb1.med.virginia. edu/biostat/s/Hmisc.html. 2003. Ref Type: Electronic Citation
16. Jassem J, Kosmidis P, Ramlau R, Zarogoulidis K, Novakova L, Breton J, Etienne PL, Seebacher C, Grivaux M, Ojala A, Aubert D, Lefresne F (2003) Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann Oncol 14: 1634-1639
17. Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zatloukal P, Lemarie E, Hartmann W, Novakova L, O'Brien M, Depierr A (2001) A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 12: 1375-1381
18. Jensen LH, Osterlind K, Rytter C (2008) Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 62: 85-91
19. Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, Fujita Y, Teramukai S, Fukushima M, Furuse K (2008) Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, openlabel, phase III study. Lancet Oncol 9: 1135-1142
20. Laack E, Dickgreber N, Muller T, Knuth A, Benk J, Lorenz C, Gieseler F, Durk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK (2004) Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 22: 2348-2356
21. Le LK, Myon E, Hill S, Riou-Franca L, Scott D, Sidhu M, Dunlop D, Launois R (2007) Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur J Health Econ 8: 145-151
22. Lilenbaum RC, Chen CS, Chidiac T, Schwarzenberger PO, Thant M, Versola M, Lane SR (2005) Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 16: 97-101
23. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110-115
24. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12: 1643-1649
25. O'Brien ME, Szczesna A, Karnicka H, Zatloukal P, Eisen T, Hartmann W, Kasan P, Longerey B, Lefresne F (2004) Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study 11. Ann Oncol 15: 921-927
26. Rajeswaran A, Trojan A, Burnand B, Giannelli M (2008) Efficacy and side effects of cisplatin-and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59: 1-11
27. Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM (2008) Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care 14: 297-306
28. Reck M, von PJ, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21: 1804-1809
29. Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, Norton A, Ashley S (2001) Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19: 1336-1343
30. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, Kies MS (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20: 1335-1343
31. Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV (2005) Randomized study of vinorelbine-gemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 49: 233-240
32. Vokes EE, Rosenberg R, Jahanzeb M, Craig J, Gralla R, Belani C, Jones S, Bigley J, Hohneker J (1994) Oral vinorelbine (Navelbine) in the treatment of advanced non-small cell lung cancer: a preliminary report. Semin Oncol 21: 35-38
33. von Plessen C, Bergman B, Andresen O, Bremnes RM, Sundstrom S, Gilleryd M, Stephens R, Vilsvik J, Aasebo U, Sorenson S (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 95: 966-973
34. Yamamoto N, Nakagawa K, Uejima H, Sugiura T, Takada Y, Negoro S, Matsui K, Kashii T, Takada M, Nakanishi Y, Kato T, Fukuoka M (2006) Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104. Cancer 107: 599-605
35. Zhang L, Zhang Y, Li N, Xu F, Pan ZK, Guan ZZ (2004) Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC). Ai Zheng 23: 1455-1458